|
US4650750A
(en)
|
1982-02-01 |
1987-03-17 |
Giese Roger W |
Method of chemical analysis employing molecular release tag compounds
|
|
US4709016A
(en)
|
1982-02-01 |
1987-11-24 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
|
US5650270A
(en)
|
1982-02-01 |
1997-07-22 |
Northeastern University |
Molecular analytical release tags and their use in chemical analysis
|
|
US5516931A
(en)
|
1982-02-01 |
1996-05-14 |
Northeastern University |
Release tag compounds producing ketone signal groups
|
|
US5217866A
(en)
|
1985-03-15 |
1993-06-08 |
Anti-Gene Development Group |
Polynucleotide assay reagent and method
|
|
US5360811A
(en)
|
1990-03-13 |
1994-11-01 |
Hoechst-Roussel Pharmaceuticals Incorporated |
1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
|
|
JP3545461B2
(ja)
|
1993-09-10 |
2004-07-21 |
エーザイ株式会社 |
二環式ヘテロ環含有スルホンアミド誘導体
|
|
AU4596096A
(en)
|
1994-09-06 |
1996-03-27 |
Banyu Pharmaceutical Co., Ltd. |
Novel carbapenem derivative
|
|
US7083983B2
(en)
|
1996-07-05 |
2006-08-01 |
Cancer Research Campaign Technology Limited |
Inhibitors of the interaction between P53 and MDM2
|
|
US6281230B1
(en)
|
1996-07-24 |
2001-08-28 |
Celgene Corporation |
Isoindolines, method of use, and pharmaceutical compositions
|
|
US6306663B1
(en)
|
1999-02-12 |
2001-10-23 |
Proteinex, Inc. |
Controlling protein levels in eucaryotic organisms
|
|
US6831155B2
(en)
|
1999-12-08 |
2004-12-14 |
President And Fellows Of Harvard College |
Inhibition of p53 degradation
|
|
DE60037345T2
(de)
|
1999-12-10 |
2008-11-13 |
Pfizer Products Inc., Groton |
Pyrrolo(2,3-d)pyrimidin-Verbindungen
|
|
DE10002509A1
(de)
|
2000-01-21 |
2001-07-26 |
Gruenenthal Gmbh |
Substituierte Glutarimide
|
|
EP1259514B9
(en)
|
2000-02-28 |
2005-11-09 |
Sugen, Inc. |
3-(pyrolyllactone)-2-indolinone compounds as kinase inhibitors
|
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
|
US7208157B2
(en)
|
2000-09-08 |
2007-04-24 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
WO2002020740A2
(en)
|
2000-09-08 |
2002-03-14 |
California Institute Of Technology |
Proteolysis targeting chimeric pharmaceutical
|
|
DE60217322T2
(de)
|
2001-04-27 |
2007-10-04 |
Zenyaku Kogyo K.K. |
Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält
|
|
PL370823A1
(en)
|
2001-12-18 |
2005-05-30 |
F.Hoffmann-La Roche Ag |
Cis-2,4,5- triphenyl-imidazolines and their use in the treatment of tumors
|
|
ATE397925T1
(de)
|
2001-12-18 |
2008-07-15 |
Hoffmann La Roche |
Cis-imidazoline als mdm2-hemmer
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
AU2003243594A1
(en)
|
2002-06-13 |
2003-12-31 |
Johns Hopkins University |
Novel boronic chalcone derivatives and uses thereof
|
|
PT1536827E
(pt)
|
2002-08-14 |
2009-03-20 |
Silence Therapeutics Ag |
Utilização de proteína cinase n beta
|
|
US20050227932A1
(en)
|
2002-11-13 |
2005-10-13 |
Tianbao Lu |
Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
|
|
AU2004212928A1
(en)
|
2003-02-13 |
2004-09-02 |
Bioveris Corporation |
Deazaflavin compounds and methods of use thereof
|
|
US6916833B2
(en)
|
2003-03-13 |
2005-07-12 |
Hoffmann-La Roche Inc. |
Substituted piperidines
|
|
AU2004228668B2
(en)
|
2003-04-03 |
2011-10-27 |
Park Funding, Llc |
PI-3 kinase inhibitor prodrugs
|
|
ES2382377T3
(es)
|
2003-05-30 |
2012-06-07 |
Gemin X Pharmaceuticals Canada Inc. |
Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer
|
|
US7425638B2
(en)
|
2003-06-17 |
2008-09-16 |
Hoffmann-La Roche Inc. |
Cis-imidazolines
|
|
US7132421B2
(en)
|
2003-06-17 |
2006-11-07 |
Hoffmann-La Roche Inc. |
CIS-imidazoles
|
|
EP1692153A4
(en)
|
2003-07-03 |
2007-03-21 |
Univ Pennsylvania |
INHIBITION OF EXPRESSION OF SYK-KINASE
|
|
US7829742B2
(en)
|
2003-12-22 |
2010-11-09 |
Johns Hopkins University |
Boronic acid aryl analogs
|
|
WO2005097820A1
(en)
|
2004-04-06 |
2005-10-20 |
Korea Research Institute Of Bioscience And Biotechnology |
Peptides for inhibiting mdm2 function
|
|
WO2005113556A1
(en)
|
2004-05-13 |
2005-12-01 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
|
JP4814228B2
(ja)
|
2004-05-18 |
2011-11-16 |
エフ．ホフマン−ラ ロシュ アーゲー |
新規ｃｉｓ−イミダゾリン
|
|
GB0419481D0
(en)
|
2004-09-02 |
2004-10-06 |
Cancer Rec Tech Ltd |
Isoindolin-1-one derivatives
|
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ｏｘ４０ｌ抗體
|
|
AU2006206458B2
(en)
|
2005-01-19 |
2012-10-25 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
US7759383B2
(en)
|
2005-02-22 |
2010-07-20 |
The Regents Of The University Of Michigan |
Small molecule inhibitors of MDM2 and the uses thereof
|
|
CA2599476A1
(en)
|
2005-03-16 |
2006-09-21 |
F. Hoffmann-La Roche Ag |
Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments
|
|
PT2343320T
(pt)
|
2005-03-25 |
2018-01-23 |
Gitr Inc |
Anticorpos anti-gitr e as suas utilizações
|
|
PL1888550T3
(pl)
|
2005-05-12 |
2014-12-31 |
Abbvie Bahamas Ltd |
Promotory apoptozy
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
US7576082B2
(en)
|
2005-06-24 |
2009-08-18 |
Hoffman-La Roche Inc. |
Oxindole derivatives
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
US7402325B2
(en)
|
2005-07-28 |
2008-07-22 |
Phoenix Biotechnology, Inc. |
Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
|
|
US7989622B2
(en)
|
2005-10-07 |
2011-08-02 |
Exelixis, Inc. |
Phosphatidylinositol 3-kinase inhibitors and methods of their use
|
|
JP5191391B2
(ja)
|
2005-11-01 |
2013-05-08 |
ターゲジェン インコーポレーティッド |
キナーゼのビ−アリールメタ−ピリミジン阻害剤
|
|
SG10202003901UA
(en)
|
2005-12-13 |
2020-05-28 |
Incyte Holdings Corp |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
|
|
UA96283C2
(uk)
|
2005-12-23 |
2011-10-25 |
Зіланд Фарма А/С |
Модифіковані міметики лізину
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
US7495007B2
(en)
|
2006-03-13 |
2009-02-24 |
Hoffmann-La Roche Inc. |
Spiroindolinone derivatives
|
|
WO2007129161A2
(en)
|
2006-04-26 |
2007-11-15 |
F. Hoffmann-La Roche Ag |
Thieno [3, 2-d] pyrimidine derivative useful as pi3k inhibitor
|
|
US7737174B2
(en)
|
2006-08-30 |
2010-06-15 |
The Regents Of The University Of Michigan |
Indole inhibitors of MDM2 and the uses thereof
|
|
DK2526933T3
(en)
|
2006-09-22 |
2015-05-18 |
Pharmacyclics Inc |
Inhibitors of Bruton's tyrosine kinase
|
|
US7638548B2
(en)
|
2006-11-09 |
2009-12-29 |
Hoffmann-La Roche Inc. |
Spiroindolinone derivatives
|
|
AU2007332493A1
(en)
|
2006-12-14 |
2008-06-19 |
Daiichi Sankyo Company, Limited |
Imidazothiazole derivatives
|
|
KR101566840B1
(ko)
|
2007-03-12 |
2015-11-06 |
와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 |
페닐 아미노 피리미딘 화합물 및 이의 용도
|
|
WO2008118802A1
(en)
|
2007-03-23 |
2008-10-02 |
Regents Of The University Of Minnesota |
Therapeutic compounds
|
|
US7625895B2
(en)
|
2007-04-12 |
2009-12-01 |
Hoffmann-Le Roche Inc. |
Diphenyl-dihydro-imidazopyridinones
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
US7553833B2
(en)
|
2007-05-17 |
2009-06-30 |
Hoffmann-La Roche Inc. |
3,3-spiroindolinone derivatives
|
|
PE20090717A1
(es)
|
2007-05-18 |
2009-07-18 |
Smithkline Beecham Corp |
Derivados de quinolina como inhibidores de la pi3 quinasa
|
|
US8591886B2
(en)
|
2007-07-12 |
2013-11-26 |
Gitr, Inc. |
Combination therapies employing GITR binding molecules
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
EP2219671A4
(en)
|
2007-11-09 |
2011-02-09 |
Salk Inst For Biological Studi |
USE OF TAM RECEPTOR INHIBITORS AS IMMU ENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS
|
|
US10047066B2
(en)
|
2007-11-30 |
2018-08-14 |
Newlink Genetics Corporation |
IDO inhibitors
|
|
HUE029767T2
(en)
|
2008-03-11 |
2017-04-28 |
Incyte Holdings Corp |
JAK inhibitor azetidine and cyclobutane derivatives
|
|
CA2722159C
(en)
|
2008-04-24 |
2016-04-05 |
Newlink Genetics Corporation |
Substituted phenylimidazole compounds and their use as ido inhibitors
|
|
WO2009156652A1
(fr)
|
2008-05-29 |
2009-12-30 |
Saint-Gobain Centre De Recherches Et D'etudes Europeen |
Structure en nid d'abeille a base de titanate d'aluminium
|
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
EP3255060A1
(en)
|
2008-12-09 |
2017-12-13 |
F. Hoffmann-La Roche AG |
Anti-pd-l1 antibodies and their use to enhance t-cell function
|
|
US8921037B2
(en)
|
2008-12-16 |
2014-12-30 |
Bo Han |
PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair
|
|
KR101790802B1
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-ｇｉｔｒ 항체
|
|
EP2493862B1
(en)
|
2009-10-28 |
2016-10-05 |
Newlink Genetics Corporation |
Imidazole derivatives as ido inhibitors
|
|
UA107814C2
(uk)
|
2009-11-12 |
2015-02-25 |
Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган |
Спірооксіндольні антагоністи мdм2
|
|
ES2722300T3
(es)
|
2009-12-10 |
2019-08-09 |
Hoffmann La Roche |
Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
|
|
US8658170B2
(en)
|
2010-01-06 |
2014-02-25 |
Joseph P. Errico |
Combination therapy with MDM2 and EFGR inhibitors
|
|
EP2542256B1
(en)
|
2010-03-04 |
2019-05-22 |
MacroGenics, Inc. |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
US9169323B2
(en)
|
2010-03-05 |
2015-10-27 |
Hoffmann-La Roche Inc. |
Antibodies against human CSF-1R
|
|
JP5989547B2
(ja)
|
2010-03-05 |
2016-09-07 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
ヒトｃｓｆ−１ｒに対する抗体及びその使用
|
|
US8114621B2
(en)
|
2010-03-12 |
2012-02-14 |
Saladax Biomedical Inc. |
Lenalidomide and thalidomide immunoassays
|
|
SG184288A1
(en)
|
2010-04-09 |
2012-11-29 |
Univ Michigan |
Biomarkers for mdm2 inhibitors for use in treating disease
|
|
HRP20190047T1
(hr)
|
2010-05-04 |
2019-02-22 |
Five Prime Therapeutics, Inc. |
Protutijela koja se vežu na csf1r
|
|
JO2998B1
(ar)
|
2010-06-04 |
2016-09-05 |
Amgen Inc |
مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
|
|
CN103153335A
(zh)
|
2010-06-30 |
2013-06-12 |
布兰代斯大学 |
小分子靶定的蛋白质降解
|
|
MX337040B
(es)
|
2010-09-09 |
2016-02-09 |
Pfizer |
Moleculas de union a 4-1bb.
|
|
JP2014500870A
(ja)
|
2010-11-12 |
2014-01-16 |
ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン |
スピロ−オキシインドールｍｄｍ２アンタゴニスト
|
|
CA2823837A1
(en)
|
2010-12-07 |
2012-06-14 |
Yale University |
Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
NO2694640T3
(enExample)
|
2011-04-15 |
2018-03-17 |
|
|
|
JP6072771B2
(ja)
|
2011-04-20 |
2017-02-01 |
メディミューン，エルエルシー |
Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
|
|
WO2012155066A2
(en)
|
2011-05-11 |
2012-11-15 |
Shaomeng Wang |
Spiro-oxindole mdm2 antagonists
|
|
KR101764096B1
(ko)
|
2011-11-28 |
2017-08-02 |
메르크 파텐트 게엠베하 |
항-ｐｄ-ｌ1 항체 및 그의 용도
|
|
RU2658603C2
(ru)
|
2011-12-15 |
2018-06-21 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против человеческого csf-1r и их применения
|
|
WO2013106646A2
(en)
|
2012-01-12 |
2013-07-18 |
Yale University |
Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
|
|
KR102668696B1
(ko)
|
2012-01-12 |
2024-05-29 |
예일 유니버시티 |
E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
|
|
KR20140127855A
(ko)
|
2012-02-06 |
2014-11-04 |
제넨테크, 인크. |
Csf1r 억제제를 사용하는 조성물 및 방법
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
RU2670743C9
(ru)
|
2012-05-11 |
2018-12-19 |
Файв Прайм Терапьютикс, Инк. |
Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)
|
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
|
AU2013299627C1
(en)
|
2012-08-09 |
2018-05-31 |
Celgene Corporation |
Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
WO2014044622A1
(en)
|
2012-09-19 |
2014-03-27 |
F. Hoffmann-La Roche Ag |
2-oxo-2,3,4,5-tetrahydro-1 h-benzo[b]diazepines and their use in the treatment of cancer
|
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
|
GB201311910D0
(en)
|
2013-07-03 |
2013-08-14 |
Glaxosmithkline Ip Dev Ltd |
Novel Compounds
|
|
MX2016006432A
(es)
|
2013-11-18 |
2016-07-19 |
Hoffmann La Roche |
Tetrahidro-benzodiazepinonas.
|
|
US10233176B2
(en)
|
2013-11-27 |
2019-03-19 |
Signalchem Lifesciences Corporation |
Aminopyridine derivatives as TAM family kinase inhibitors
|
|
IL286427B2
(en)
|
2014-01-28 |
2024-08-01 |
Mayo Found Medical Education & Res |
Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
|
|
MA39749A
(fr)
|
2014-03-17 |
2017-01-25 |
Hoffmann La Roche |
Dérivés de pipéridine-dione
|
|
US20160058872A1
(en)
|
2014-04-14 |
2016-03-03 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
RU2738833C9
(ru)
|
2014-04-14 |
2022-02-28 |
Арвинас, Оперэйшнз, Инк. |
Имидные модуляторы протеолиза и способы их применения
|
|
CA2945527C
(en)
*
|
2014-04-17 |
2022-05-17 |
The Regents Of The University Of Michigan |
Mdm2 inhibitors and therapeutic methods using the same
|
|
EP3827836A1
(en)
|
2014-06-27 |
2021-06-02 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
|
|
WO2016001376A1
(en)
|
2014-07-03 |
2016-01-07 |
Boehringer Ingelheim International Gmbh |
New spiro[3h-indole-3,2´-pyrrolidin]-2(1h)-one compounds and derivatives as mdm2-p53 inhibitors
|
|
US20160022642A1
(en)
|
2014-07-25 |
2016-01-28 |
Yale University |
Compounds Useful for Promoting Protein Degradation and Methods Using Same
|
|
US10071164B2
(en)
|
2014-08-11 |
2018-09-11 |
Yale University |
Estrogen-related receptor alpha based protac compounds and associated methods of use
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2016105518A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
JP6817962B2
(ja)
|
2015-01-20 |
2021-01-20 |
アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． |
ターゲティングされたアンドロゲン受容体分解のための化合物および方法
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
EP3270917A4
(en)
|
2015-03-18 |
2018-08-08 |
Arvinas, Inc. |
Compounds and methods for the enhanced degradation of targeted proteins
|
|
GB201506871D0
(en)
|
2015-04-22 |
2015-06-03 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
CA2988414C
(en)
|
2015-06-04 |
2023-09-26 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
CN105085620B
(zh)
|
2015-06-25 |
2018-05-08 |
中山大学附属第一医院 |
一种靶向泛素化降解Smad3的化合物
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
EP3319944A4
(en)
|
2015-07-10 |
2019-04-24 |
Arvinas, Inc. |
MDM2-BASED MODULATORS OF PROTEOLYSIS AND RELATED USE METHODS
|
|
BR112017028269A2
(pt)
|
2015-07-13 |
2018-09-04 |
Arvinas Inc |
composto, composição farmacêutica, uso de uma quantidade efetiva de um composto, estado ou condição de doença, e, método para identificar um composto.
|
|
WO2017009650A1
(en)
|
2015-07-14 |
2017-01-19 |
Mission Therapeutics Limited |
Cyanopyrrolidines as dub inhibitors for the treatment of cancer
|
|
US10772962B2
(en)
|
2015-08-19 |
2020-09-15 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
WO2017059280A1
(en)
|
2015-10-02 |
2017-04-06 |
The University Of North Carolina At Chapel Hill |
Novel pan-tam inhibitors and mer/axl dual inhibitors
|
|
BR112018008918A8
(pt)
|
2015-11-02 |
2019-02-26 |
Univ Yale |
compostos de quimera proteólise dirigida e métodos para preparação e uso dos mesmos
|
|
WO2017117473A1
(en)
|
2015-12-30 |
2017-07-06 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molescules for her3 degradation and methods of use
|
|
WO2017117474A1
(en)
|
2015-12-30 |
2017-07-06 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional compounds for her3 degradation and methods of use
|
|
BR112018068906A2
(pt)
|
2016-03-16 |
2019-01-22 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo
|
|
US20170281784A1
(en)
|
2016-04-05 |
2017-10-05 |
Arvinas, Inc. |
Protein-protein interaction inducing technology
|
|
US10759808B2
(en)
*
|
2016-04-06 |
2020-09-01 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
|
SG11201808728QA
(en)
|
2016-04-06 |
2018-11-29 |
Univ Michigan Regents |
Mdm2 protein degraders
|
|
EP3454856B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
WO2017197056A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
|
ES2990061T3
(es)
|
2016-05-10 |
2024-11-28 |
C4 Therapeutics Inc |
Degronímeros espirocíclicos para la degradación de proteínas diana
|
|
WO2017201069A1
(en)
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Oxoindoline derivatives as protein function modulators
|
|
CN118436801A
(zh)
|
2016-05-20 |
2024-08-06 |
豪夫迈·罗氏有限公司 |
Protac抗体缀合物及其使用方法
|
|
GB201610147D0
(en)
|
2016-06-10 |
2016-07-27 |
Glaxosmithkline Ip Dev Ltd |
Novel compounds
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
US10925868B2
(en)
|
2016-11-10 |
2021-02-23 |
Dana-Farber Cancer Institute, Inc. |
Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
|
|
AU2017363313B2
(en)
|
2016-11-22 |
2021-06-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
|
|
IL312367A
(en)
|
2017-01-31 |
2024-06-01 |
Arvinas Operations Inc |
Cereblon ligands and bifunctional compounds comprising the same
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
CN118108706A
(zh)
|
2017-09-04 |
2024-05-31 |
C4医药公司 |
戊二酰亚胺
|
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
|
WO2019060742A1
(en)
|
2017-09-22 |
2019-03-28 |
Kymera Therapeutics, Inc |
AGENTS FOR DEGRADING PROTEINS AND USES THEREOF
|
|
WO2019084030A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
|
|
WO2019084026A1
(en)
|
2017-10-24 |
2019-05-02 |
Genentech, Inc. |
(4-HYDROXYPYRROLIDIN-2-YL) -HETEROCYCLIC COMPOUNDS AND METHODS OF USE
|
|
CN111372585A
(zh)
|
2017-11-16 |
2020-07-03 |
C4医药公司 |
用于靶蛋白降解的降解剂和降解决定子
|
|
EP3710443A1
(en)
|
2017-11-17 |
2020-09-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
IL315310A
(en)
*
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
|
WO2019140380A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
CA3090417A1
(en)
|
2018-02-23 |
2019-08-29 |
Dana-Farber Cancer Institute, Inc. |
Small molecules for inducing selective protein degradation and uses thereof
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
WO2020010227A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
|
WO2020010210A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Mertk degraders and uses thereof
|
|
JP7472103B2
(ja)
|
2018-08-22 |
2024-04-22 |
クルゲン（シャンハイ），インク． |
トロポミオシン受容体キナーゼ（ｔｒｋ）分解化合物とその使用方法
|
|
CN112912143A
(zh)
|
2018-10-08 |
2021-06-04 |
美国密歇根州立大学试剂中心 |
小分子mdm2蛋白降解剂
|
|
US20220251071A1
(en)
|
2019-05-14 |
2022-08-11 |
Wisconsin Alumni Research Foundation |
Method to make small-molecule murine double minute 2 protein (mdm2)-degrading compounds, compounds formed thereby, and pharmaceutical compositions containing them
|
|
US20230072658A1
(en)
|
2019-06-10 |
2023-03-09 |
Kymera Therapeutics, Inc. |
Smarca degraders and uses thereof
|
|
WO2021011631A1
(en)
|
2019-07-15 |
2021-01-21 |
Kymera Therapeutics, Inc. |
Fused-glutarimide crbn ligands and uses thereof
|
|
JP2023511472A
(ja)
|
2019-10-29 |
2023-03-20 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための二官能性化合物
|
|
EP4122925A4
(en)
*
|
2020-03-17 |
2024-04-17 |
Medshine Discovery Inc. |
Proteolysis regulator and method for using same
|
|
KR20230005160A
(ko)
*
|
2020-03-19 |
2023-01-09 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Mdm2 분해제 및 이의 용도
|
|
EP4255568A1
(en)
|
2020-12-03 |
2023-10-11 |
Baylor College of Medicine |
Novel ripk1 kinase targeting protacs and methods of use thereof
|
|
WO2022159644A1
(en)
|
2021-01-23 |
2022-07-28 |
Newave Pharmaceutical Inc. |
Spirocyclic mdm2 modulator and uses thereof
|
|
US20250034147A1
(en)
|
2021-09-22 |
2025-01-30 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
|
US20230233546A1
(en)
|
2021-12-15 |
2023-07-27 |
Kymera Therapeutics, Inc. |
Methods of treating cancer
|
|
US20250352535A1
(en)
|
2022-06-06 |
2025-11-20 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
|
WO2024197216A2
(en)
|
2023-03-22 |
2024-09-26 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
|
WO2024197218A2
(en)
|
2023-03-22 |
2024-09-26 |
Kymera Therapeutics, Inc. |
Deuterated mdm2 degraders and uses thereof
|
|
WO2024197221A2
(en)
|
2023-03-22 |
2024-09-26 |
Kymera Therapeutics, Inc. |
Solid forms of mdm2 degraders
|
|
WO2024197219A1
(en)
|
2023-03-22 |
2024-09-26 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|
|
WO2025096262A1
(en)
|
2023-11-01 |
2025-05-08 |
Kymera Therapeutics, Inc. |
Mdm2 degraders and uses thereof
|